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Abstract
Objectives: To assess interruptions/discontinuations of tyro-
sine kinase inhibitor (TKI) treatment in Belgian patients with 
chronic myeloid leukaemia (CML). Methods: This retrospec-
tive study included patients with TKI interruptions/discon-
tinuations of ≥4 continuous weeks (no clinical trial context) 
between May 2013 and May 2016. Data collection took place 
between October 2016 and February 2017. Results: All 60 
participants (69 interruptions/discontinuations) had chron-
ic-phase CML and 75% had at least a major molecular re-
sponse (≥MMR) at interruption/discontinuation. Most inter-
ruptions/discontinuations occurred while on imatinib 
(36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/
discontinuations occurred due to side effects/intolerance 
(46/69; 67%); other reasons included a wish to conceive 
(6/69; 9%) and attempts to achieve treatment-free remission 
(TFR) (6/69; 9%). Interruptions due to side effects occurred 
later for imatinib- or dasatinib-treated patients than for 
those on nilotinib or ponatinib. Treatment was re-initiated in 
62% (43/69) of cases. Most interruptions caused by side ef-
fects/intolerance were followed by treatment changes. All 4 
patients with ≥MR 4.5 at interruption/discontinuation and 
≥11-month follow-up who had not restarted treatment 
maintained the response. Conclusion: Although TKIs are 
used for long-term CML treatment, physicians sometimes 
recommend interruptions/discontinuations. In this study, 
interruptions/discontinuations were mainly caused by side 
effects or intolerance, rather than TFR attempts.
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Introduction
Adenosine triphosphate-competitive tyrosine kinase 
inhibitors (TKIs) targeting BCR-ABL1, the driving onco-
protein of chronic myeloid leukemia (CML), revolution-
ized patient outcomes. After the introduction of imatinib 
in the early 2000s, the more potent second-generation 
drugs, dasatinib, nilotinib, and bosutinib, followed by the 
third-generation compound, ponatinib, enriched the 
therapeutic arsenal [1]. 
Treatment discontinuation in CML is relatively fre-
quent and although there has been an increased focus on 
treatment-free remission (TFR) as a new goal of therapy 
in CML, the interruption or discontinuation of therapy 
can occur for a myriad of other reasons in the real-life set-
ting, e.g., to avoid worrying side effects including those 
predisposing to other chronic disease, eliminate low-
grade chronic toxicity that substantially impacts a pa-
tient’s quality of life, and be freed up from the daily con-
straints of medication intake. Other reasons could be a 
pregnancy or the wish to conceive, no longer needing to 
be careful about drug-drug/food-drug interactions, and 
the financial burden of targeted therapy [2–5]. 
It also needs to be noted that this broad variety of reasons 
to interrupt TKI treatment in CML are either recommend-
ed by the treating physician (e.g., in the case of a TFR at-
tempt, severe side effects, toxicity, pregnancy, and the wish 
to conceive) or not (i.e., non-adherence, which can be re-
lated to side effects and other reasons). Optimal adherence 
to CML therapy is of key importance to maximize treatment 
effectiveness. Two clinical studies (ADAGIO and Ham-
mersmith) have proven a clear correlation between adher-
ence and achieving optimal treatment response, and they 
revealed that non-adherence is indeed common in CML 
patients [6, 7]. In fact, it was demonstrated that non-adher-
ence is associated with disease progression and a 3-fold-
higher risk of poor treatment outcomes [7]. 
Although most CML patients need life-long TKI treat-
ment, the promising results of imatinib interruption in a 
small number of cases [8–10] prompted the launching of 
discontinuation trials. Subsequently, in the multi-centre 
Stopping Imatinib (STIM) study [11–13], the CML8 
(TWISTER) study from the Australasian Leukaemia and 
Lymphoma Group [14, 15], and the multi-centre obser-
vational According to Stop Imatinib (A-STIM) study 
[16], at least one-third of patients achieved TFR after in-
terrupting treatment with imatinib. TFR clinical trials 
have also been conducted with second-generation TKIs, 
including ENESTfreedom [17], ENESTop [18], STOP 
2G-TKI [19], DADI [20], and DASFREE [21]. Since mid-
2017, TFR is included in the label of nilotinib, based on 
the ENESTfreedom and ENESTop trials [17, 18]. The use 
of second-generation TKIs does not seem to improve the 
results when compared to imatinib but does appear to 
impact on the median time from treatment start to the 
attempt to stop [22]. All the studies published so far clear-
ly demonstrate that discontinuation is feasible and safe if 
performed in patients with a long-lasting deep molecular 
response (DMR), with no reports of disease progression 
or clonal evolution [22]. The last version of the 2013 Eu-
ropean LeukemiaNet recommendations suggested con-
tinuing TKI therapy indefinitely and that discontinuation 
would be appropriate only in a controlled clinical trial 
[23]. Hughes and Ross [24] reported for the first time in 
2016 how to move TFR into the clinical practice. A posi-
tion on TKI discontinuation was also taken by the NCCN 
in the new 2017 version of the CML guidelines [25]. 
In Belgium, national guidelines currently recommend 
staging of CML according to European LeukemiaNet [5, 
25] or World Health Organisation [26] criteria, and ini-
tiating first-line treatment with imatinib, nilotinib, or da-
satinib in chronic-phase (CP) patients, with careful mon-
itoring of any adverse events (AEs) and potential drug 
interactions. Nilotinib, dasatinib, bosutinib, and pona-
tinib are considered for patients resistant or intolerant to 
their first-line TKI and also for advanced-phase patients. 
According to national guidelines, interruption or discon-
tinuation of TKI treatment is recommended when severe 
skin rash or grade 3 hepatic toxicity occurs, or for female 
CP patients that have achieved a major molecular re-
sponse (MMR) for ≥2 years and are planning to conceive. 
TFR attempts are only recommended in clinical trial set-
tings for patients in a deep sustained response [27].
Treatment discontinuation in CML is relatively fre-
quent and, although there has been an increased focus on 
treatment free remission (TFR) as new goal of therapy in 
CML, therapy interruption or discontinuation can be for 
a myriad of other reasons in the real-life setting. In the 
existing literature, only a limited amount of data is cur-
rently available on this matter. We therefore conducted 
this trial to characterise TKI interruptions or discontinu-
ations in Belgian CML patients and examine the reasons 
for TKI interruption or discontinuation in real-life situa-
tions with related national guidelines.
Methods
Study Design and Participants
The study on the interruption or discontinuation of tyrosine 



















   
   
   
   
   


























KLE (A Belgian Retrospective Study on the Interruption or Dis-
continuation of Tyrosine Kinase Inhibitor Treatment in Chronic 
Myeloid Leukaemia) was a phase-IV, retrospective, observational, 
cross-sectional study based on data collected from chart reviews of 
CML patients from 13 Belgian haematology centres between Oc-
tober 2016 and February 2017. No treatment was administered as 
part of this study. All clinical decisions were made as per the treat-
ing physician’s best clinical judgement.
Eligible participants were CML patients who had ≥1 TKI inter-
ruptions/discontinuations (i.e., either interrupting temporarily or 
with the intention to discontinue indefinitely) of ≥4 continuous 
weeks (regardless of the reason) outside the context of a clinical 
trial between 31 May 2013 and 31 May 2016. Patients with an in-
terruption of < 4 weeks were excluded to avoid evaluating those 
whose treatment was interrupted only briefly because of transient 
toxicity. We only included patients with a TKI interruption/dis-
continuation of ≥4 continuous weeks. As such, the study detected 
only the persistent phase of adherence according to the taxonomy 
of Vrijens et al. [28] (i.e., when a prescribed therapy is discontin-
ued early), but not the non-implementation phase of adherence 
which may be more common in CML (i.e., the prescribed therapy 
is still taken but not in a fully compliant manner).
Study Objectives
The objectives of this observational study were to assess the 
predefined characteristics of patients and other parameters of TKI 
treatment interruption/discontinutation. A post hoc sub-group 
analysis was carried out, in patients followed for at least 11 months, 
of treatment interruptions/discontinuations that occurred be-
tween May 2013 and May 2015.
The predefined characteristics of patients and other outcomes 
of TKI treatment interruption/discontinuation were collected and 
analysed. The information collected as per protocol was inserted 
into an electronic case report form; no personally identifiable data 
was included. 
Captured data consisted of the characteristics of patients, 
treatment interruption, and, if applicable, reinitiation of treat-
ment. Patient characteristics included age, gender, Sokal risk 
score, CML phase, and disease duration. Characteristics of the 
treatment interruption included the duration and reason of the 
TKI interruption; the duration, type and line of TKI therapy that 
was interrupted; the time between TKI interruption and the first 
BCR-ABL1 RT-qPCR molecular test; and the depth of (molecu-
lar) response of the patient and its duration prior to TKI interrup-
tion. 
Five levels of TKI response were used in this study: a complete 
haematological response (CHR), a complete cytogenetic response 
(CCyR), and 3 levels of MR, namely, MMR (also referred to as 
MR3; a 3-log reduction from the standardised baseline or ≤0.1% 
BCR-ABL1 on the International Scale as assessed by quantitative 
reverse-transcriptase PCR), MR4 (a 4-log reduction from the stan-
dardised baseline or ≤0.01% BCR-ABL1), and MR4.5 (a 4.5-log 
reduction from the standardised baseline or ≤0.0032% BCR-ABL1) 
or deeper [20].
Outcomes
If the patient had reinitiated therapy, the outcomes of the treat-
ment interruption/discontinuation that were captured included 
the date of reinitation and the depth of the response as well as the 
reasons for reinitation and the type of TKI used.
Statistical Methods
All analyses were performed with macro-enriched Microsoft 
Excel 2016 MSO (16.0.8201.2102) 32-bit version. They were per-
formed on the overall population (for most outcomes), the subset 
of patients who interrupted/discontinued treatment due to preg-
nancy or the wish to conceive, and the subset of patients followed 
for at least 11 months. 
All analyses were descriptive, and no statistical hypotheses 
were formulated. Missing data was excluded from the database 
when calculating percentages of patients or interruptions.
Some patients had multiple TKI treatment interruptions/dis-
continuations, so the number of interruptions/discontinuations 
was higher than the number of participants. Most analyses used 
variables related to interruptions/discontinuations (69 cases), so 
the number of interruptions/discontinuations was considered for 
calculating the statistical parameters instead of the number of par-
ticipants (n = 60). 
A contract research organization, XPE Pharma & Science, per-




Sixty CML patients participated in the study; 51 had 
1 and 9 had 2 TKI interruptions/discontinuations, 
 respectively (Table 1). The total number of cap-
Table 1. Whole-population analysis of 60 CML patients who inter-
rupted or discontinued TKI treatment
n %
Whole population






Not available 22 37
Mean age at latest interruption/discontinuation
≤61 years 27 45
>61 years 33 55






MR4.5 or deeper 25 36
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tured TKI interruptions/discontinuations was therefore 
69.
Patients were homogeneously distributed by gender; 
mean age was 61.0 years. All patients had CP CML. The 
Sokal risk score was low/intermediate in 61% (37/60) of 
patients, high in 2% (1/60), and not available in 37% 
(22/60).
Of all treatment interruptions/discontinuations, 36% 
(25/69) occurred in patients with MR4.5 or deeper, 16% 
(11/69) in patients with MR4, 23% (16/69) in patients 
with MMR, and 25% (17/69) in patients without at least 
an MMR.
Treatment Interruptions/Discontinuations
The median time between CML diagnosis and TKI 
treatment interruption/discontinuation was 363 weeks; 
patients were treated with TKIs (i.e., the specific TKI 
treatment that was interrupted/discontinued) for a me-
dian time of 169 weeks before the interruption/discon-
tinuation. 
Most TKI interruptions/discontinuations occurred 
while on imatinib or dasatinib, i.e., 49% (34/69) in pa-
tients taking imatinib and 29% (20/69) in patients taking 
dasatinib (the latter occurred mostly when taken as sec-
ond-line treatment) (Table 2).
The duration of the MR prior to TKI treatment inter-
ruption/discontinuation in the overall population 
ranged between 0 and 615 weeks; the median duration 
was 37 weeks. The respective durations of the MR prior 
to TKI interruption/discontinuation are described ac-
cording to sub-characteristics in online supplementary 
Table 1 (for all online suppl. material, see www.karger.
com/doi/10.1159/000499329).
The main reasons for TKI treatment interruption/dis-
continuation were side effects or intolerance (in 46/69 
cases [67%]), TFR attempts (6/69 [9%]), and the wish to 
conceive (6/69 [9%]). Of the interruptions/discontinua-
tions due to side effects or intolerance, no significant in-
fluence of gender and age was observed (online suppl. 
Table 2). 
For 17% (12/69) and 25% (17/69) of the interruptions/
discontinuations, patients had a low and intermediate So-
kal risk score, respectively. For 1 interruption/discontin-
uation, the patient had a high Sokal risk score, and for 
23% (16/69) no score was not available. The median dura-
tion of the treatment interruption/discontinuation was 
112 days (Table 3). 
Twenty-eight of the 69 (41%) TKI interruptions/dis-
continuations were in patients on first-line TKI treat-
ment, and a comparable number (25/69; 36%) in patients 
on second-line therapy (online suppl. Table 2).
Interruptions/discontinuations of imatinib treatment 
were the longest (median duration 186 days) when com-
pared to other TKIs. The median duration of treatment 
interruption/discontinuation was longest in patients 
wishing to conceive (253 days) and shortest if they took 
place at the request of the patient (59 days). Interrup-
tions/discontinuations due to side effects or intolerance 
lasted for a median 98 days, although this varied greatly, 
from 29 to 904 days.
Interruptions/discontinuations lasted a median of 24 
weeks in study participants with an MMR (approx. 21 and 
17 weeks in participants with MR4 and MR4.5 or deeper, 
respectively), while in those with CHR and CCyR, they 
lasted a median of 13 and 10 weeks, respectively (Table 
3). The median follow-up time between interruption/dis-
continuation and first molecular test did not vary much 
with different reasons for interruption/discontinuation 
(56 days for those due to side effects or intolerance, 49 
days for TFR attempts, 47 days in patients wishing to con-
ceive, and 48 days upon patient request). Those with less 
than MMR at treatment interruption/discontinuation 
had a shorter median time between interruption/discon-
tinuation and first molecular test (Table 4).
Of the 34 patients (40 interruptions/discontinua-
tions) that were followed for at least 11 months after 
interrupting or discontinuing TKI treatment, 7 were 
still off treatment at the end of the study. Of these 7, all 
4 with an MR4.5 or deeper response at the time of dis-
continuation maintained this response, 2 with MR4 at 
the time of discontinuation had an MMR, and 1 with 
MMR at the time of discontinuation had CCyR at the 
last follow-up.
Table 2. Number of interruptions/discontinuations (I/Ds) accord-
ing to type and line of treatment received prior to interruption/
discontinuation in 69 patients (whole-population analysis)
I/Ds, n I/Ds, %
Imatinib
As 1st-line 23 33
As line ≥2 11 16
Nilotinib
As 1st-line 3 4
As line ≥2 9 13
Dasatinib
As 1st-line 2 3
As line ≥2 18 26
Ponatinib



















   
   
   
   
   


























Table 3. Duration of TKI treatment interruption/discontinuation overall and per sub-characteristic, and reason 
for interruption/discontinuation in 69 patients (whole-population analysis)
n Duration, days
mean median range
Chronic phase of CML 69 175.7 112 29–904
Female gender 33 173.6 107 32–904
Sokal risk score
Low 18 237.8 141 33–904
Intermediate 25 140.6 89 32–833
High 1 345.0 345 345–345
Not available 25 159.4 140 29–536
Age at latest interruption/discontinuation1
≤64 years (median) 33 184.2 132 29–833
>64 years (median) 36 168.0 94 32–904
≤61 years (mean) 30 191.3 136 29–833
>61 years (mean) 39 163.8 96 32–904
Line of TKI treatment
1st 28 239.8 184 29–904
2nd 25 133.3 85 33–425
3rd 4 126.3 113 91–189
4th 4 293.5 263 112–536
5th 5 54.8 43 35–105
6th 3 42.3 44 36–47
TKI received prior to interruption/discontinuation
Imatinib 34 214.9 186 29–904
Nilotinib 12 168.7 89 36–833
Dasatinib 20 130.3 85 33–686
Bosutinib 0 – – –
Ponatinib 3 63.7 44 35–112
Other 0 – – –
Interval between CML diagnosis and treatment interruption/discontinuation1
≤363 weeks (median) 35 136.4 91 29–833
>363 weeks (median) 34 216.3 183 35–904
≤426 weeks (mean) 39 150.6 91 29–833
>426 weeks (mean) 30 208.5 183 35–904
Duration of the TKI treatment that was interrupted/discontinued1
≤169 weeks (median) 35 180.7 91 32–904
>169 weeks (median) 34 170.6 148 29–536
≤238 weeks (mean) 42 168.0 91 32–904
>238 weeks (mean) 27 187.7 185 29–536
Response at the time of TKI treatment interruption/discontinuation
CHR 15 107.3 91 32–345
CCyR 2 70.5 71 36–105
MMR 16 199.2 168 35–833
MR4 11 233.9 149 33–686
MR4.5 or deeper 25 184.6 124 29–904
Reason for treatment interruption/discontinuation interruption/discontinuation
TFR attempt 6 174.2 186 36–358
A wish to conceive 6 271.0 253 165–420
Spontaneous request of the patient 2 58.5 59 32–85
Due to side effects or intolerance 46 166.1 98 29–904
Other 9 188.7 96 42–833
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Treatment Interruptions/Discontinuations Due to 
Side Effects
In total, 67% (46/69) of interruptions/discontinua-
tions were due to TKI side effects or intolerance (online 
suppl. Table 2). These occurred mostly while the patients 
were taking imatinib (20/46; 43%) or dasatinib (17/46; 
37%) (Table 5). Among patients reinitiating treatment af-
ter interrupting/discontinuing due to side effects, more 
reinitiations with TKI switching occurred for dasatinib 
(8/17; 47%) than for imatinib (5/20; 25%). Treatment in-
terruptions/discontinuations due to side effects seemed 
to occur later in patients on imatinib (median 268 weeks) 
than in those on dasatinib (51 weeks), but then lasted lon-
ger (165 vs. 84 days). Very early treatment interruptions/
discontinuations (after a median of 9 and 4 weeks, respec-
tively) due to side effects were observed for nilotinib and 
ponatinib.
Treatment Interruptions/Discontinuations Due to 
Pregnancy or the Wish to Conceive
In total, 6 patients interrupted/discontinued treat-
ment due to their wish to conceive, 3 men and 3 women 
(Table 6). All were younger than 40 years, in the CP of 
CML. Three had a low Sokal risk score and 1 an interme-
diate Sokal risk score; no data was available for the re-
maining 2. All patients interrupting/discontinuing treat-
ment to conceive had at least MMR at the time of inter-
ruption/discontinuation: 4/6 with an MMR, 1 with an 
Table 4. Median time between treatment interruption/discontinuation (I/D) and first molecular test
I/Ds, n Median time, days
Overall 62 51




MR4.5 or deeper 24 58
Reason for treatment interruption/discontinuation
TFR attempt 6 49
A wish to conceive 6 47
Spontaneous request of the patient 2 48
Due to side effects or intolerance 41 56
Other 7 71
Table 5. Exploratory statistics on various parameters according to TKI before treatment interruption/discon-





Patients who restarted 
treatment with a different TKIc




n % n %
Imatinib 20 43 268 165 13 38 5 28
Nilotinib 6 13 9 65 6 18 4 22
Dasatinib 17 37 51 84 13 38 8 44
Bosutinib 0 – – – 0 – 0 –
Ponatinib 3 7 4 44 2 6 1 6
Other 0 – – – 0 – 0 –
No treatment interruptions/discontinuations were recorded for bosutinib or other TKIs. I/D, interruption/
discontinuation; n, number of treatment interruptions/discontinuations (overall) or treatment reinitiations 
(restarted treatment).



















   
   
   
   
   


























MR4, and 1 with an MR4.5 or deeper. At the time of 
treatment interruption/discontinuation, 4/6 patients 
were using imatinib. Only 2 subsequently reinitiated 
treatment, both due to a loss of response. One had a com-
plete relapse (no CHR) and the other had CHR before 
reinitiation. Both reinitiated treatment with the TKI 
used before interruption (i.e., 1 with imatinib and 1 with 
nilotinib).
The median duration of interruption/discontinuation 
of TKI treatment among these patients was 253 days. All 
patients wishing to conceive interrupted/discontinued 
the treatment for ≥5 months.
Treatment ReInitiations
Treatment was reinitiated after 62% (43/69) of inter-
ruptions/discontinuations, 20 of which were reinitiated 
with a different TKI from the one used before interrup-
tion/discontinuation (Table 7). Most reinitiations (34/43; 
79%) occurred following a treatment interruption/dis-
continuation due to side effects or intolerance. Of the pa-
tients on imatinib before the interruption who reinitiated 
treatment, 18% (6/34) switched to a different TKI. Pa-
tients previously on nilotinib, dasatinib, and ponatinib 
reinitiated with a different TKI in 42% (5/12), 40% (8/20), 
and 33% (1/3) of cases, respectively. Among patients who 
reinitiated treatment with a different TKI, most interrup-
tions/discontinuations were due to side effects or intoler-
ance to the previous TKI. 
None of the patients who interrupted TKI treatment 
for a TFR attempt had their treatment reinitiated (0/6). 
Of the 6 who interrupted the treatment due to the wish to 
conceive, 33% (2/6) had treatment reinitiated. One of 2 
patients who had interrupted TKI treatment by sponta-
neous request had treatment reinitiated. Of the patients 
that had interrupted TKI treatment due to side effects or 
intolerance, 74% (34/46) had treatment reinitiated. 
The reasons for treatment reinitiation were either loss 
of response in 47% (20/43) of the cases, the resolution of 
side effects in 37% (16/43), and another reason in 16% 
(7/43).
Of the 40 interruptions/discontinuations that were 
followed up for at least 11 months, 33 treatment reinitia-
tions were reported until study end. These included 4 pa-
tients with an MR4.5 or deeper at the time of discontinu-
ation who reinitiated treatment due to a resolution of side 
effects but maintained their response.
Patients who reinitiated treatment had higher BCR-
ABL1 expression at the time of reinitiation than at the 
time of treatment interruption/discontinuation (not 
shown).
Discussion
This is the first study to assess interruptions/discon-
tinuations of TKI treatment in Belgian CML patients in a 
real-life setting. All 60 patients with TKI interruptions/
discontinuations were in the CP of CML, mainly with a 
low or intermediate Sokal risk score. Out of a total of 69 
TKI interruptions/discontinuations recorded, more than 
three-quarters occurred while on first- or second-line 
treatment, and nearly half while on imatinib. These find-
ings are consistent with the fact that imatinib is a well-
Table 6. Summary of results for 6 patients who interrupted/dis-
continued treatment due to a pregnancy or the wish to conceive
Characteristics n %
Chronic phase of CML 6 100




Not available 2 33
Age at interruption/discontinuation
≤40 years 6 100




TKI received prior to interruption/discontinuationa
Imatinib 4 67
Nilotinib 2 33
Depth of response at the time of TKI treatment 
interruption/discontinuation
MR3 (MMR) 4 67
MR4 1 17
MR4.5 or deeper 1 17
Treatment reinitiated
No 4 67
Yes (due to a loss of response) 2 33
Treatment reinitiated with the same TKI
Yes 2 33
Depth of response at the time of TKI treatment reinitiationb
CHR 1 50
No CHRc 1 50
a All patients were receiving either imatinib or nilotinib.
b In a total of 2 patients.
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established treatment option in the front-line CML set-
ting in Belgium. 
Although TKI treatment is currently viewed as a life-
long treatment, discontinuing or interrupting it is consid-
ered in certain cases, e.g., when side effects impact severe-
ly on the quality of life, or the case of a pregnancy or the 
wish to conceive. Health care costs can also be a limiting 
factor. So far, cessation of treatment is not yet daily clini-
cal practice for physicians. Current recommendations 
state that following TKI treatment stop, the MR should 
be monitored once per month during the first 6–12 
months, although only 4 analyses per year are reimbursed 
by the Belgian health authorities [5, 24]. An MMR is con-
sidered optimal for survival, but to achieve a successful 
discontinuation of treatment, a sustained DMR is re-
quired [25]. In our survey, the MR at the time of treat-
ment discontinuation/interruption was MMR or deeper 
in three-quarters of the cases. These MRs at the time of 
treatment discontinuation/interruption were achieved 
after a median of 85, 27, and 63 weeks, respectively, in 
patients with MMR, MR4, and MR4.5.
The main reason for TKI treatment interruption/dis-
continuation identified in our study was the presence of 
side effects or intolerance; however, treatment was later 
reinitiated in three-quarters of these cases, and with a dif-
ferent TKI in 39%. Most interruptions/discontinuations 
due to side effects or intolerance occurred in patients on 
imatinib (43%) and dasatinib (37%). This reflects current 
practice because most patients were being treated with 
imatinib or dasatinib at the time of the study. Less than 
one-tenth of the interruptions/discontinuations occurred 
due to a TFR attempt; none of these patients reinitiated 
treatment for the duration of our study.
The median duration of TKI treatment interruption/
discontinuation depended on the response at the time of 
interruption/discontinuation, with the low responders 
(CHR and CCyR) having a shorter interruption/discon-
tinuation and a quicker monitoring of the response after 
treatment interruption/discontinuation than partici-
pants with at least MMR. The TKI treatment interrup-
tion/discontinuation was longer for patients with at least 
MMR, diagnosed for a longer time, and treated for > 1 
year with a first- or second-line TKI. The longest inter-
ruptions/discontinuations were recorded for patients on 
imatinib, which is also in line with the fact that imatinib 
was the most widely used TKI at the time of this study.
Following almost two-thirds of TKI interruptions/dis-
continuations, treatment was reinitiated. As expected, if 
treatment was interrupted/discontinued due to side ef-
fects or intolerance, it was then reinitiated (in almost 




Reason for I/D Overall populationa Patients who
restarted treatmentb
Patients who restarted 
treatment with a different TKIc
n % median I/D
duration, days
n % n %
Imatinib TFR attempt 5 7 189 0 0 0 –
A wish to conceive 4 6 282 1 2 0 –
Spontaneous request of the patient 1 1 32 0 – 0 –
Due to side effects or intolerance 20 29 165 13 30 5 25
Other 4 6 161 3 7 1 5
Nilotinib TFR attempt 1 1 182 0 – 0 –
A wish to conceive 2 3 227 1 2 0 –
Spontaneous request of the patient 1 1 85 1 2 0 –
Due to side effects or intolerance 6 9 65 6 14 4 20
Other 2 3 452 1 2 1 5
Dasatinib Due to side effects or intolerance 17 25 84 13 30 8 40
Other 3 4 86 2 5 0 –
Ponatinib Due to side effects or intolerance 3 4 44 2 5 1 5
No I/Ds were recorded for bosutinib or other TKIs. I/D, interruption/discontinuation; n, number of treatment I/Ds (overall) or reinitiations 
(restarted treatment).



















   
   
   
   
   


























three-quarters of cases). Three-quarters of these reinitia-
tions occurred with a different TKI. Most low responders 
and patients with an MMR reinitiated treatment. The 
treatment reinitiation rate was higher in patients with a 
shorter interval between CML diagnosis and TKI treat-
ment interruption/discontinuation and a shorter dura-
tion of TKI treatment. This is consistent with the current 
knowledge of successful TFR.
At treatment reinitiation, no CHR was reported in 
19% of the cases; a CHR or CCyR was reported in about 
half of the cases. 
The main reason for TKI treatment reinitiation was 
the loss of response after treatment interruption/discon-
tinuation or the resolution of side effects. The first was 
more frequent in patients with MMR or a better response 
at the time of the interruption/discontinuation, while the 
latter occurred more frequently in patients with a low re-
sponse. Of note, no CML patients developed accelerated-
phase CML or a blast crisis; all remained in CP-CML.
As expected, follow-up of MR after interruption/dis-
continuation was fast (an overall median time of 51 days). 
However, this is slightly longer than the 1-month interval 
currently recommended in Belgian guidelines in cases of 
TFR attempts and can probably be partly attributed to the 
lack of reimbursement.
Both male and female participants interrupted/discon-
tinued treatment in an attempt to conceive. Although the 
impact of TKI treatment on fertility or pregnancy outcome 
is not fully elucidated, there is no formal contraindication 
for procreation while on imatinib and dasatinib in male 
patients [29, 30]. However, female patients should discon-
tinue TKI treatment during conception and pregnancy, 
and all pregnancies should be planned to achieve at least an 
MMR before interruption/discontinuation. In our study, 
all patients wishing to conceive had an MMR or better re-
sponse, and only one-third reinitiated treatment during the 
time the survey was conducted, due to a loss of response. 
Currently, Belgian experts recommend a treatment inter-
ruption/discontinuation of ≥3 months to attempt procre-
ation [27]; in our study, the median length of interruption/
discontinuation was 253 days (approx. 8.3 months).
Even though TKI therapies in CML are considered a 
life-long treatment, this study has shown that in a real-life 
setting, interruption or discontinuation occurs quite fre-
quently in the CML population and for a variety of rea-
sons.
The proportion of patients who interrupted treatment 
to attempt a long-term TFR was very small in this study 
(9% of all cases). This is in line with the fact that national 
guidelines as well as the most recent ELN guidelines of 
2013, applicable at the time of TKI interruption of the pa-
tients in this study, suggest continuing TKI therapy in-
definitely and that discontinuation is appropriate only in 
a controlled clinical trial [5].
A few patients interrupted TKI treatment due to the 
wish to conceive (9% of all cases). Indeed, conception and 
pregnancy are contraindicated during TKI treatment [5]. 
Belgian national guidelines also state that female patients 
who wish to conceive are advised to discontinue any TKI 
during conception and pregnancy [27].
The presence of side effects or intolerance was the 
most frequently reported reason to interrupt or discon-
tinue TKI treatment in our study (67% of all cases). The 
management of side effects is increasingly important as 
therapy is potentially for life and multiple TKIs are avail-
able [2]. Belgian national guidelines recommend discon-
tinuing TKI therapy in cases of severe hepatic toxicity, 
severe skin rash, pancreatitis, and pulmonary hyperten-
sion [27]. In addition, it is known that low-grade chronic 
toxicities that substantially impact a patient’s quality of 
life (and for other reasons) can lead to non-adherence 
which is commonly reported in CML. The 2013 ELN rec-
ommendations state that a reduction or interruption of 
treatment must only be done if optimal management of 
the AE cannot be accomplished in other ways, and fre-
quent monitoring is needed to detect resolution of the AE 
as early as possible [23].
Eight patients with a follow-up of at least 11 months 
had MR4.5 or deeper at discontinuation; 4 of them re-
started treatment due to a resolution of side effects while 
maintaining their response and 4 remained with MR4.5 
and did not restart TKI treatment at the end of the study.
This retrospective study had several limitations. First, 
to set a threshold for significant treatment interruptions/
discontinuations in terms of duration, patients needed to 
have a TKI interruption/discontinuation of at least 4 con-
tinuous weeks to be included in the study. As such, we 
were not able to collect any real-life data on shorter TKI 
interruptions/discontinuations, which are also frequently 
observed in CML and contribute to non-adherence. We 
also did not make a distinction between therapy interrup-
tions that were recommended and those not recommend-
ed by the treating physician. The study was retrospective, 
with a limited follow-up time (i.e., the interval between 
the TKI interruption and data collection). This meant 
that some variables were not captured for patients who 
were still off therapy at time of data collection. The kinet-
ics of the response after the TKI interruption in the func-
tion of time were also not captured. No information was 
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